← ANALYST RATINGS · TIPRANKS
Moderna (MRNA): analyst forecast and price target
Analyst consensus
Hold3 Buy14 Hold3 Sell
Ratings of 20 analysts in the last 3 months12-month forecast
Based on 20 price targets given in the last 3 months, the average target is $108, the highest $180, the lowest $40.00. The average is −50.5% from the last price of $218.
Analyst ratings 21
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $247 → $228−7.7% | Hold | +4.6% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $242 → $223−7.9% | Hold | +2.3% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $244 → $225−7.8% | Hold | +3.2% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $233 → $215−7.7% | Hold | −1.4% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $250 → $230−8.0% | Hold | +5.5% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $246 → $227−7.7% | Hold | +4.1% | Reiterated | 17.10.26on TipRanks 07:05 | — | |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $130 | Hold | −40.4% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $80.00 | Sell | −63.3% | Reiterated | 15.10.26on TipRanks 07:30 | +4.2%next day −6.7% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $120 → $137+14.2% | Hold | −37.2% | Assigned | 15.10.26on TipRanks 06:20 | +4.2%next day −6.7% | ↗ |
| Alec Stranahan★★★★★★★★★★#1533 · hits 52% · avg +8.4% | Bank of America Securities | — | Hold | — | Reiterated | 09.10.26on TipRanks 08:25 | +13.6%next day −4.9% · 5 days −1.1% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $95.00 | Hold | −56.4% | Assigned | 07.10.26on TipRanks 08:15 | +5.1%next day +0.7% · 5 days +16.2% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | — | Sell | — | Reiterated | 28.09.26on TipRanks Sep 29 00:55 | −0.1%next day +3.3% · 5 days +1.8% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | $45.00 | Hold | −79.4% | Reiterated | 24.09.26on TipRanks Sep 25 06:50 | +7.1%next day +1.5% · 5 days −2.6% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $60.00 → $150+150.0% | Hold | −31.2% | Reiterated | 22.09.26on TipRanks 09:25 | +5.6%next day +0.5% · 5 days +12.6% | ↗ |
| Nico Chen★★★★★★★★★★#2913 · hits 59% · avg +9.8% | DBS | $150 | Hold | −31.2% | Reiterated | 11.09.26on TipRanks 12:55 | +4.5%next day +2.3% · 5 days +7.1% | ↗ |
| Cory Kasimov★★★★★★★★★★#276 · hits 59% · avg +18.9% | Evercore ISI | $80.00 | Hold | −63.3% | Reiterated | 11.09.26on TipRanks 09:46 | +4.5%next day +2.3% · 5 days +7.1% | ↗ |
| Harry Gillis★★★★★★★★★★#1398 · hits 69% · avg +21.0% | Berenberg Bank | $45.00 → $100+122.2% | Hold | −54.1% | Reiterated | 10.09.26on TipRanks Sep 11 04:15 | +1.3%next day +4.5% · 5 days +15.1% | ↗ |
| Simon Baker CFA★★★★★★★★★★#9955 · hits 42% · avg −4.8% | Rothschild & Co Redburn | $40.00 → $81.00+102.5% | Sell | −62.8% | Downgrade | 03.09.26on TipRanks 05:25 | −2.3%next day −1.8% · 5 days −2.1% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $180 | Buy | −17.4% | Upgrade | 27.08.26on TipRanks Aug 28 07:27 | −5.3%next day −3.1% · 5 days +4.0% | ↗ |
| Alexandria Hammond★★★★★★★★★★#7870 · hits 50% · avg +0.6% | Wolfe Research | — | Hold | — | Upgrade | 25.08.26on TipRanks 05:50 | +14.0%next day −5.8% · 5 days −2.3% | ↗ |
| Eliana Merle★★★★★★★★★★#4163 · hits 45% · avg +3.0% | Barclays | $48.00 → $125+160.4% | Hold | −42.7% | Reiterated | 24.08.26on TipRanks 06:25 | −4.0%next day +14.0% · 5 days +0.6% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $50.00 → $150+200.0% | Hold | −31.2% | Reiterated | 20.08.26on TipRanks 06:50 | −22.7%next day +8.4% · 5 days +6.0% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | — | Hold | — | Reiterated | 19.08.26on TipRanks 09:55 | +176.8%next day −22.7% · 5 days −13.8% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Upgrade | 19.08.26on TipRanks 08:35 | +176.8%next day −22.7% · 5 days −13.8% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $77.00 | Buy | −64.7% | Reiterated | 06.08.26on TipRanks 07:01 | −4.1%next day +9.2% · 5 days +17.0% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $40.00 | Hold | −81.7% | Reiterated | 31.07.26on TipRanks Aug 3 04:40 | −6.1%next day −0.8% · 5 days +4.4% | ↗ |
| Mani Foroohar★★★★★★★★★★#11266 · hits 43% · avg −2.1% | Leerink Partners | $17.00 → $12.00−29.4% | Sell | −94.5% | Reiterated | 11.02.26on TipRanks Feb 12 10:45 | −3.5%next day +0.6% · 5 days +23.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Moderna
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $110 at a price of $193 (−42.7%); now: $108 at $218 (−50.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 5 | 4 | 4 |
| Hold | 30 | 42 | 43 | 44 | 31 | 26 |
| Sell | 8 | 12 | 12 | 10 | 6 | 6 |
Earnings and sales forecast
Next report: 06.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.09 (from $-1.58 to $-0.53). Last quarter: $-1.97.
Sales
Next quarter’s sales estimate — $892M (from $836M to $1.1B). Last quarter: $145M.
Best top-analyst consensus in the sector · Healthcare
About Moderna
- CEO: Stéphane Bancel
- Employees: 4,700
- 325 Binney Street, Cambridge, MA, 02142, US
- www.modernatx.com
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗